On August 26, Boston Scientific fell 3.73% in pre-market trading, trading at approximately $48.01 per share. The decline was triggered by the company's disclosure of a cybersecurity incident that has caused disruptions to its global operations.

According to a filing submitted to the U.S. Securities and Exchange Commission, a cybersecurity event has impacted Boston Scientific's order processing and shipping operations on a global scale. The company stated it has not yet determined whether the incident is reasonably likely to have a material impact on the company, and is still assessing the potential scope and severity of the situation. No specific recovery timeline has been provided.

The cybersecurity disclosure compounds existing headwinds for the stock. In late July, the company reported Q2 adjusted EPS of $0.86 beating the $0.83 estimate, but simultaneously lowered full-year guidance to adjusted EPS of $3.28-$3.32, below the consensus of $3.36. The Watchman business is expected to see mid-to-high single-digit revenue declines in the second half, and multiple analysts subsequently cut price targets, with Argus downgrading the stock to Hold.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)